Open AccessSpecificity and Continuity of Schizophrenia and Bipolar Disorder: Relation to Biomarkers
Author(s) -
Yuji Yamada,
Madoka Matsumoto,
Kazuki Iijima,
Tomiki Sumiyoshi
Publication year - 2020
Publication title -
current pharmaceutical design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 159
eISSN - 1873-4286
pISSN - 1381-6128
DOI - 10.2174/1381612825666191216153508
Subject(s) - bipolar disorder , schizoaffective disorder , schizophrenia (object oriented programming) , psychiatry , mood , psychosis , psychology , modalities , cognition , clinical psychology , medicine , social science , sociology
Schizophrenia and bipolar disorder overlap considerably in terms of symptoms, familial patterns, risk genes, outcome, and treatment response. This article provides an overview of the specificity and continuity of schizophrenia and mood disorders on the basis of biomarkers, such as genes, molecules, cells, circuits, physiology and clinical phenomenology. Overall, the discussions herein provided support for the view that schizophrenia, schizoaffective disorder and bipolar disorder are in the continuum of severity of impairment, with bipolar disorder closer to normality and schizophrenia at the most severe end. This approach is based on the concept that examining biomarkers in several modalities across these diseases from the dimensional perspective would be meaningful. These considerations are expected to help develop new treatments for unmet needs, such as cognitive dysfunction, in psychiatric conditions.